CHARLOTTE, N.C. (Oct. 10, 2024) – Today, Amwins Group Benefits announced the expansion of its Gene Therapy Solutions (GTS) program. Now covering 15 revolutionary gene and cell therapies, the proprietary program helps employers mitigate the cost of treatments, stay ahead of new treatments receiving FDA approval, and protect their bottom line.
“Our Gene Therapy Solutions program addresses the growing needs of employers,” said Harley Barnes, chief executive officer at Stealth Partner Group. “Expanding from GTS-5 to GTS-15 helps to ensure that our clients have the comprehensive support they need to face the high cost of gene therapy treatments, while making the process simpler and more efficient. We remain dedicated to offering the best solutions for cost containment, helping employers maximize their budgets while providing cutting-edge protection for their workforce.”
Exclusively offered through Stealth Partner Group and Amwins Accident and Health Underwriters, the GTS-15 program provides sustainable, revolutionary strategies that help employers face unexpected, high-dollar gene therapy claims with confidence.
“Gene therapy is transforming the lives of patients, but with costs for treatment reaching up to $4.25 million, this is a challenge that employers shouldn’t face alone,” said Meredith Hunter, senior vice president at Stealth Partner Group. “Our GTS-15 program provides the critical support needed to keep employers ahead of these rising costs while ensuring the best care for their employees.”
Key Program Benefits:
Amwins’ expanded program covers groundbreaking treatments, providing crucial reimbursement to group health plans and their coordinating stop-loss carriers for qualified claims. As the FDA continues to approve new therapies, GTS-15 prepares employers to handle the financial impact of these high-cost treatments.
GTS-15 covers 11 of the 13 approved gene therapies, 3 cell therapy treatments and 1 maintenance medication with some of these therapies reaching as high as 4.25 million dollars. As gene therapies rapidly evolve, so does the need for smart, forward-thinking protection strategies. By partnering with Stealth Partner Group and Amwins Accident & Health Underwriters, employers gain access to the expertise and flexibility required to navigate these unprecedented changes in the healthcare landscape.
For a full list of covered treatments and more information, visit Amwins Gene Therapy Solutions.
About Amwins
Amwins is one of the largest independent wholesale distributors of specialty insurance products in the U.S. dedicated to serving retail insurance agents by providing property and casualty products, specialty group benefit products, and administrative services. Based in Charlotte, N.C., the company operates through more than 155 offices globally and handles premium placements in excess of $33 billion annually.
About Stealth Partner Group
Stealth Partner Group, an Amwins Company, was founded in 2009 and has grown to be one of the largest specialized general agencies in the country. The firm partners with brokers, consultants, and third-party administrators (TPAs) to negotiate, implement, and assist in managing medical stop-loss and ancillary benefits with the nation's top-tier carriers. With 15 offices across the U.S., Stealth offers its clients more than 150 years of collective experience in the stop-loss and ancillary insurance marketplace. For more information, visit stealthpartnergroup.com.
About Amwins Accident & Health Underwriters
Amwins Accident & Health Underwriters comprises two long-standing MGUs, Beacon Risk Strategies and Strategic Underwriting Solutions, each with a track record of delivering full spectrum underwriting expertise and unrivaled service. For more information, visit Amwins Accident & Health Underwriters
